Vito Spataro
Overview
Explore the profile of Vito Spataro including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
7
Citations
78
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
2.
Spataro V, Buetti-Dinh A
Br J Cancer
. 2022 May;
127(5):788-799.
PMID: 35501388
POH1/Rpn11/PSMD14 is a highly conserved protein in eukaryotes from unicellular organisms to human and has a crucial role in cellular homoeostasis. It is a subunit of the regulatory particle of...
3.
Mosku N, Heesen P, Studer G, Bode B, Spataro V, Klass N, et al.
Cancers (Basel)
. 2022 Apr;
14(7).
PMID: 35406402
The ratio of malignancy in suspicious soft tissue and bone neoplasms (RMST) has not been often addressed in the literature. However, this value is important to understand whether biopsies are...
4.
Peters S, Curioni-Fontecedro A, Nechushtan H, Shih J, Liao W, Gautschi O, et al.
J Thorac Oncol
. 2018 Aug;
13(12):1897-1905.
PMID: 30096481
Introduction: Approximately 1% to 4% of NSCLC tumors harbor erb-b2 receptor tyrosine kinase 2 (ERBB2) mutation; there is no approved targeted treatment for this subgroup. Methods: Patients with stage IV...
5.
Delfine V, Bernasconi E, Bardelli D, Spataro V, Fusi-Schmidhauser T
J Pain Palliat Care Pharmacother
. 2017 Mar;
31(1):43-44.
PMID: 28287358
Refractory pain is a common manifestation in an oncologic palliative care setting and represents a major challenge for health care professionals involved in care provision. The underlying neoplasm and its...
6.
7.
Spataro V, Simmen K, Realini C
Anticancer Res
. 2003 Jan;
22(6C):3905-9.
PMID: 12553011
Background: Identification of multidrug resistance (MDR) factors is crucial for designing chemotherapeutic strategies. Aberrant expression and dysfunction of proteasome subunits have been involved in malignant transformation and in cell resistance...